Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade F 31.62 2.00% 0.62
NKTR closed up 2.0 percent on Tuesday, April 23, 2019, on approximately normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 8

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NKTR trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Outside Day Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Inside Day Range Contraction 2.00%
Oversold Stochastic Weakness 2.00%
Pocket Pivot Bullish Swing Setup -0.19%
Stochastic Reached Oversold Weakness -0.19%
Lower Bollinger Band Touch Weakness -0.19%

Older signals for NKTR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Chemistry Biotechnology Biopharmaceutical Manufacturing Pharmaceutical Pain Drugs Pharmacology Ovarian Cancer Chronic Pain Morphinans Anti Infectives Metastatic Breast Cancer Opioid Antagonists Pegylation Treatment Of Metastatic Breast Cancer Diols Metastatic Colorectal Cancer Opioid Induced Constipation
Is NKTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 92.17
52 Week Low 29.22
Average Volume 1,696,499
200-Day Moving Average 44.6476
50-Day Moving Average 36.4554
20-Day Moving Average 33.728
10-Day Moving Average 33.454
Average True Range 1.5003
ADX 22.44
+DI 15.0856
-DI 31.1876
Chandelier Exit (Long, 3 ATRs ) 32.4991
Chandelier Exit (Short, 3 ATRs ) 34.5509
Upper Bollinger Band 37.1894
Lower Bollinger Band 30.2666
Percent B (%b) 0.2
BandWidth 20.52538
MACD Line -1.1249
MACD Signal Line -0.8935
MACD Histogram -0.2314
Fundamentals Value
Market Cap 4.94 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -22.59
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.23
Resistance 3 (R3) 34.00 32.89 33.80
Resistance 2 (R2) 32.89 32.23 33.01 33.65
Resistance 1 (R1) 32.26 31.82 32.58 32.49 33.50
Pivot Point 31.15 31.15 31.31 31.27 31.15
Support 1 (S1) 30.52 30.49 30.84 30.75 29.74
Support 2 (S2) 29.41 30.08 29.53 29.59
Support 3 (S3) 28.78 29.41 29.45
Support 4 (S4) 29.01